Last edition
News about "Anti-CD122 antibody"
argenx to Acquire Forte Biosciences
argenx will acquire Forte Biosciences to add the first-in-class anti-CD122 antibody FB102, expanding its immunology pipeline.
Anti-CD122 Antibody | 27/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members